Renal Research Institute, New York, NY, USA.
Nephrol Dial Transplant. 2012 Aug;27(8):3255-63. doi: 10.1093/ndt/gfr808. Epub 2012 May 7.
Various biochemical and physiological variables are related to outcome in hemodialysis (HD) patients. However, the prognostic implications of trends in body temperature (BT) in this population have not yet been studied. The aim of this study was to assess the relationship between trends in BT and outcome in incident HD patients.
Six thousand seven hundred and forty-two incident HD patients without thyroid disease from the Renal Research Institute were followed for 1 year. Patients were divided into tertiles of initial pre-dialysis BT (Tertile 1: ≤ 36.47°C, Tertile 2: > 36.47 to 36.71°C and Tertile 3: > 36.7°C) and further classified according to the change in BT (increased: > 0.01°C/month, decreased: less than -0.01°C/month and stable, with change between - 0.01 and + 0.01°C/month) during the first year of treatment. The reference group is Tertile 2 of initial temperature with stable BT. Cox regression was used for survival analyses. Analyses were repeated for patients who survived the first year and were treated for ≥ 1 month in Year 2.
BT decreased in 2903 patients, remained stable in 2238 patients and increased in 1601 patients. After adjustment for multiple risk factors, hazard ratios (HRs) for mortality were higher for those groups in whom, irrespective of the initial BT, BT increased or declined, as compared to the reference group during follow-up (HR between 1.46 and 2.27).
The best survival was observed in the group with the highest BT at baseline and stable BT during the follow-up period (HR 0.50).
各种生化和生理变量与血液透析(HD)患者的预后相关。然而,该人群中体温(BT)趋势的预后意义尚未得到研究。本研究旨在评估 HD 患者中 BT 趋势与预后之间的关系。
本研究纳入了来自肾脏研究所的 6742 名无甲状腺疾病的新发生 HD 患者,随访时间为 1 年。患者根据初始透析前 BT 分为三分位(Tertile 1:≤36.47°C;Tertile 2:36.47-36.71°C;Tertile 3:>36.7°C),并根据治疗第一年 BT 的变化(增加:>0.01°C/月;减少:< -0.01°C/月;稳定,变化在-0.01 和+0.01°C/月之间)进一步分类。参考组为初始温度三分位 2 组中 BT 稳定的患者。采用 Cox 回归进行生存分析。对生存超过 1 年且在第 2 年治疗时间≥1 个月的患者进行了重复分析。
2903 名患者的 BT 下降,2238 名患者的 BT 稳定,1601 名患者的 BT 升高。调整多个危险因素后,与参考组相比,初始 BT 无论高低,无论 BT 升高或下降,在随访期间的死亡率均更高(HR 为 1.46-2.27)。
在基线时 BT 最高且随访期间 BT 稳定的患者组中,生存最佳(HR 0.50)。